Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens.
Ravindranath
Y
Y
Children's Hospital of Michigan, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
Taub
J W
JW
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003845:Deoxycytosine Nucleotides / Q000378:metabolism; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004314:Down Syndrome / Q000150:complications*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology
D003845:Deoxycytosine Nucleotides; D003561:Cytarabine; C024107:2'-deoxycytidine 5'-triphosphate